<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77228">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01898845</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011X1101</org_study_id>
    <nct_id>NCT01898845</nct_id>
  </id_info>
  <brief_title>A Phase I Study of LEE011 in Asian Patients</brief_title>
  <official_title>A Phase I Study of LEE011 in Asian Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency (PMDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate safety and tolerability to estimate the MTD and/or recommended dose
      for expansion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open label, dose finding, phase I study of oral single agent LEE011,
      administered once daily.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>First cycle (28 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) and/or recomended dose (RD)</measure>
    <time_frame>First cycle (28 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of LEE011</measure>
    <time_frame>from informed consent till 28 days after end of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessed by incidence, duration and severity of adverse events and serious adverse events; changes in clinical laboratory values, vital signs and ECGs; tolerability of study drug (dose interruption, dose reduction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of LEE011</measure>
    <time_frame>every week up to first 4 weeks, once a week in the subsequent 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentration of LEE011 and PK parameters (e.g. Cmax and AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>every 2 months until 28 days after end of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess preliminaly anti-tumor activity based on RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>every 2 months until 28 days after end of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess preliminaly anti-tumor activity based on RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>every 2 months until 28 days after end of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess preliminaly anti-tumor activity based on RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>every 2 months until 28 days after end of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess preliminaly anti-tumor activity based on RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>every 2 months until 28 days after end of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess preliminaly anti-tumor activity based on RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
    <time_frame>every 2 months until 28 days after end of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess preliminaly anti-tumor activity based on RECIST</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>LEE011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEE011</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <arm_group_label>LEE011</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a histologically confirmed diagnosis of a solid tumor

          -  ECOG PS &lt;2

          -  Good organ function at screening visit

          -  A sufficient interval mast have elapsed between the last dose of prior anti-cancer
             therapy

        Exclusion Criteria:

          -  Impairment of GI function

          -  Patients with concurrent severe and/or uncontrolled concurrent medical conditions

          -  Known diagnosis of HIV or active viral hepatitis

          -  Pregnant or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+81337978748</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>July 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
